Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $1.00 on Thursday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company’s 50-day moving average price is $1.07 and its 200 day moving average price is $1.05. The company has a market cap of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.04. The company had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. Sell-side analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in Cytosorbents in the fourth quarter worth approximately $30,000. Renaissance Technologies LLC raised its stake in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. bought a new position in Cytosorbents during the fourth quarter valued at about $99,000. Finally, Geode Capital Management LLC grew its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.